Back to results
US 12,331,024 B2Granted
Substituted naphthyl P38alpha mitogen-activated protein kinase inhibitors
AssigneeGen1E Lifesciences Inc.
InventorsAdam Galan, Wendy Luo, Ritu Lal
Life of this patent
Estimating the term…
Abstract
Substituted naphthyl p38α mitogen-activated protein kinase inhibitors, pharmaceutical compositions thereof, and the use of the substituted naphthyl p38α mitogen-activated protein kinase inhibitors and pharmaceutical compositions thereof for treating diseases are disclosed.
Claims32
A compound having the structure of Formula (6):
- or a pharmaceutically acceptable salt thereof, wherein,
- R1 is selected from C1-4 alkanediyl, C1-4 heteroalkanediyl, substituted C1-4 alkanediyl, and substituted C1-4 heteroalkanediyl;
- R2 is a substituted heterocycloalkyl moiety selected from a bicyclic substituted C5-12 heterocycloalkyl ring, a substituted C5 heterocycloalkyl, and a substituted C7 heterocycloalkyl, wherein,
- the substituted heterocycloalkyl moiety comprises the heteroatomic groups N and O;
- and
- R2 is bonded to R1 through a nitrogen heteroatom of the substituted heterocycloalkyl moiety;
- R3 is selected from —C(═O)— and —SO2—;
- R4 is —N(R5)2 wherein each R5 is independently selected from hydrogen and C1-4 alkyl;
- and
- each substituent is independently selected from —OH, ═O, —NH2, —NO2, C1-6 alkyl, C3-6 cycloalkyl, C6 aryl, C1-6 heteroalkyl, C1-6 heterocycloalkyl, and C5-6 heteroaryl.
7 more elements
A compound having the structure of Formula (6):
- or a pharmaceutically acceptable salt thereof, wherein,
- R1 is selected from C1-4 alkanediyl, C1-4 heteroalkanediyl, substituted C1-4 alkanediyl, and substituted C1-4 heteroalkanediyl;
- R2 is a substituted C5-12 heterocycloalkyl moiety, wherein,
- the substituted C5-12 heterocycloalkyl moiety comprises the heteroatomic groups N and O;
- and
- R2 is bonded to R1 through a nitrogen heteroatom of the substituted C5-12 heterocycloalkyl moiety;
- R3 is selected from —C(═O)— and —SO2—;
- R4 is —N(R5)2 wherein each R5 is independently selected from hydrogen and C1-4 alkyl;
- and
- each substituent is independently selected from —OH, ═O, —NH2, —NO2, C1-6 alkyl, C3-6 cycloalkyl, C6 aryl, C1-6 heteroalkyl, C1-6 heterocycloalkyl, and C5-6 heteroaryl,
- wherein a substituent of the substituted C5-12 heterocycloalkyl moiety is bonded to the carbon atom adjacent to the nitrogen atom bonded to R1.
8 more elements
A method of treating a disease in a patient comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound having the structure of Formula (6):
- or a pharmaceutically acceptable salt thereof, wherein,
- R1 is selected from C1-4 alkanediyl, C1-4 heteroalkanediyl, substituted C1-4 alkanediyl, and substituted C1-4 heteroalkanediyl;
- R2 is a substituted C5-12 heterocycloalkyl moiety, wherein,
- the substituted C5-12 heterocycloalkyl moiety comprises the heteroatomic groups N and O;
- and
- R2 is bonded to R1 through a nitrogen heteroatom of the substituted C5-12 heterocycloalkyl moiety;
- R3 is selected from —C(═O)— and —SO2—;
- R4 is —N(R5)2 wherein each R5 is independently selected from hydrogen and C1-4 alkyl;
- and
- each substituent is independently selected from —OH, ═O, —NH2, —NO2, C1-6 alkyl, C3-6 cycloalkyl, C6 aryl, C1-6 heteroalkyl, C1-6 heterocycloalkyl, and C5-6 heteroaryl,
- wherein the disease is an age-related disease, and wherein the age-related disease is selected from hearing loss, muscle degeneration, Werner's syndrome, cellular aging, and Alzheimer's disease.
8 more elements
Dependencies are inferred from the claim text.